Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Age-Related Macular Degeneration (AMD) is a progressive retinal disease that leads to central vision loss, particularly in older adults, and remains a major driver of ophthalmic innovation. Globally, AMD affects over 200 million people, with prevalence rising sharply after age 60. By 2040, cases are expected to approach 300 million. The Age-Related Macular Degeneration pipeline analysis by Expert Market Research highlights expanding therapeutic development aimed at slowing progression and improving long-term visual outcomes.
-
Major companies involved in the age-related macular degeneration pipeline analysis include Novartis AG, Adverum Biotechnologies, and others.
-
Leading drugs currently in the pipeline include KH658 and others.
-
The rising global shift toward gene-editing, RPE-cell regeneration, and complement-pathway-targeting therapies, which are accelerating investment, partnership activity, and differentiated late-stage candidate advancement across both dry and neovascular AMD segments, are poised to drive the pipeline landscape for age-related macular degeneration.
Report Coverage
The age-related macular degeneration Pipeline Analysis Report by Expert Market Research gives comprehensive insights into age-related macular degeneration therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for age-related macular degeneration. The age-related macular degeneration report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The age-related macular degeneration pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with age-related macular degeneration treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to age-related macular degeneration.
Read more about this report - Request a Free Sample
Age-Related Macular Degeneration Pipeline Outlook
Age-related macular degeneration (AMD) is a progressive retinal disorder leading to loss of central vision, especially in older adults. The disease significantly affects quality of life and represents a major cause of vision impairment in aging populations worldwide.
Age-related macular degeneration treatment for the neovascular (“wet”) form currently relies on intravitreal injections of anti–vascular endothelial growth factor (VEGF) agents such as ranibizumab, aflibercept, and brolucizumab, which work by inhibiting abnormal blood vessel growth and associated fluid leakage. In September 2025, Sanofi’s investigational gene therapy SAR402663 received fast-track designation from the FDA, a landmark step toward a one-time treatment potentially reducing the need for repeated injections.
Age-Related Macular Degeneration Epidemiology
Age-related macular degeneration (AMD) represents a major global cause of irreversible vision loss, particularly among adults aged 60 years and older. Current estimates indicate that approximately 200 million people worldwide live with AMD, a figure projected to approach 300 million by 2040. In the United States, the burden is expected to reach 5.4 million individuals by 2050. Although AMD is most common among Caucasian populations, emerging evidence indicates a rising prevalence of both dry AMD and neovascular forms among Asian and African American groups, reflecting evolving demographic and epidemiological patterns.
Age-Related Macular Degeneration – Pipeline Therapeutic Assessment
This section of the report covers the analysis of age-related macular degeneration drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The age-related macular degeneration pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Oligonucleotides
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Age-Related Macular Degeneration Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total age-related macular degeneration clinical trials. Phase I includes 31% of candidates and the phase II dominates with 38%, followed by 22% in phase III. Together, these distributions highlight a robust mid-stage development landscape, reflecting sustained innovation and steady progression toward late-stage clinical validation.
Age-Related Macular Degeneration Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the age-related macular degeneration pipeline analysis include small molecules, monoclonal antibodies, oligonucleotides, and peptides. The age-related macular degeneration report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for age-related macular degeneration. The drug molecule categories covered under the age-related macular degeneration pipeline analysis include small, biologics, gene therapies, and more. The age-related macular degeneration report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for age-related macular degeneration. For example, in October 2025, the Eydenzelt (aflibercept-boav) biosimilar, a VEGF-inhibiting biologic, was approved by the FDA as a treatment for neovascular (wet) AMD, broadening options beyond the original branded therapy.
Age-Related Macular Degeneration Clinical Trials – Key Players
The EMR report for the age-related macular degeneration pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed age-related macular degeneration therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in age-related macular degeneration clinical trials:
- Bio-Thera Solutions
- Perceive Biotherapeutics, Inc.
- EyebioKorea, Inc.
- Benobio Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Novartis AG
- Opthea Limited
- EyePoint Pharmaceuticals
- 4D Molecular Therapeutics
- Adverum Biotechnologies
Age-Related Macular Degeneration – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for age-related macular degeneration. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of age-related macular degeneration drug candidates.
Biological: BAT5906
BAT5906 is a humanized recombinant anti-VEGF monoclonal antibody developed by Bio‑Thera Solutions for ocular disorders. It works by binding vascular endothelial growth factor (VEGF), inhibiting pathological neovascularization and fluid leakage in retina, thereby reducing macular edema or neovascularization. Currently in Phase III for wet age-related macular degeneration (w-AMD), BAT5906 has shown promising visual acuity and retinal-thickness improvements, offering potentially longer-lasting efficacy than existing anti-VEGF therapies.
DRUG: KH658
KH658 is an adeno-associated virus (AAV)-based gene therapy candidate under early clinical development for ocular indications, including age-related macular degeneration. The therapy is being evaluated for delivery via the suprachoroidal space and is intended to support sustained intraocular expression of therapeutic proteins involved in regulating pathological angiogenesis. While the precise transgene and long-term clinical benefits remain under investigation, KH658 represents an emerging gene-based approach aimed at improving treatment durability and reducing the burden associated with frequent intraocular injections.
DRUG: EB-203
EB-203 is a novel ophthalmic-route therapeutic in development by EyeBioKorea for neovascular (wet) AMD. EB-203 is administered topically rather than via injection. It is currently being evaluated in a Phase IIa trial for safety and efficacy in wet AMD patients. If effective, EB-203 could provide a non-invasive alternative to intra-ocular injections, improving patient comfort and treatment adherence. This approach reflects ongoing efforts to expand treatment options and improve patient experience in wet AMD management.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Age-Related Macular Degeneration Pipeline Insight Report
- Which companies/institutions are leading the age-related macular degeneration drug development?
- Which company is leading the age-related macular degeneration pipeline development activities?
- What is the current age-related macular degeneration commercial assessment?
- What are the opportunities and challenges present in the age-related macular degeneration pipeline landscape?
- What is the efficacy and safety profile of age-related macular degeneration pipeline drugs?
- Which company is conducting major trials for age-related macular degeneration drugs?
- Which companies/institutions are involved in age-related macular degeneration collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in age-related macular degeneration?
Reasons To Buy This Report
The Age-Related Macular Degeneration Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for age-related macular degeneration. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into age-related macular degeneration collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Age-Related Macular Degeneration Market
Dry Age-Related Macular Degeneration Pipeline Analysis Report
Neovascular Age-Related Macular Degeneration Treatment Market
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share